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Introduction: The global protozoan parasite, Toxoplasma gondii, infects many  warm-blooded
animals and humans by employing different transmission routes. There have been some
recent studies on the probable relevance of infectious agents and diabetes. Therefore,
we  conducted a systematic review and meta-analysis to identify the possible association
between chronic toxoplasmosis and diabetes mellitus.
Methods: This study was conducted following the general methodology recommended for
systematic reviews and meta-analysis. Nine English literature databases (Google scholar,
PubMed, Scopus, Web of science, Science Direct, Ovid, ProQuest, IngentaConnect, and Wiley
Online Library) were searched, up to January 2016. Random effects model was used to
determine odds ratios and their 95% conﬁdence intervals.
Results: Our review resulted in a total of seven publications meeting the inclusion criteria.
Because of signiﬁcant heterogeneity, we estimated a common OR by a random effects model
at  1.10 (95% CI = 0.13–9.57) with p = 0.929 and 2.39 (95% CI = 1.20–4.75) with p = 0.013 for type
1  and type 2 diabetes mellitus, respectively.
Conclusion: Despite the limitations such as low number of studies, this meta-analysis sug-
gests  chronic toxoplasmosis as a possible risk factor for type 2 DM.  However, based on
random effects model no statistically signiﬁcant association was observed between T. gondii
and  type 1 DM. It is highly recommended for researchers to carry out more accurate studieserstaaiming to better und©  2016 Sociedade Brasil
open  access article unde
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Introduction
The ubiquitous parasitic protozoan, Toxoplasma gondii,  is
one of the most successful microorganism on the planet
owing to quite a lot of compatibility to many  host species,
especially mammals, various transmission pathways (e.g.
food, water, congenital, blood transfusion, organs transplant,
etc.) and approximately involving one-third of the human
population.1–4 Being the category B priority pathogen with
zoonotic signiﬁcance, Toxoplasma has frequently been asso-
ciated with congenital complications (such as hydrocephalus,
stillbirth and abortion) as well as neuropathic anomalies, pre-
dominantly in high risk populations, i.e. pregnant women
and immunocompromised hosts.2,5–7 While unusual, there
are some evidence that T. gondii parasites may possibly have
an undiscovered role in the putative pathogenesis of autoim-
mune diseases.8
A group of chronic metabolic disorders, speciﬁed as
“Diabetes”, are of medical importance with widespread dis-
tribution, especially in persons with high-calorie diets. They
are distinguished by hyperglycemia elicited by the deﬁcien-
cies in the insulin hormone release (type 1 diabetes) and/or
failure to respond properly to insulin in target cells (type 2 dia-
betes), and this condition is probably overwhelmed by genetic
elements, autoimmune processes, and environmental factors.
According to scientiﬁc evaluations, it is anticipated that the
number of diabetic patients will reach 522 million individuals
by 2030.9 Recently, some reports have spotlighted the proba-
ble relevance of diabetes mellitus (DM) and infectious agents
like Helicobacter pylori10 and Coxsakie B4 virus.11 In this case,
the Apicomplexan parasite, T. gondii,  has been proposed as a
likely cause of diabetes, and existing information nearly predi-
cate on this issue.12–16 Hence, this review was intended to shed
light on the possible association between toxoplasmosis and
diabetes.
Methods
Ethical  aspects
As this review did not involve any human or animal subjects,
therefore ethical approval was not required.
Search  strategy
A systematic review was premised on screening the liter-
ature published online in English language up to January
2016, in order to address the association between toxoplas-
mosis and diabetes. The search was conducted on Google
scholar, PubMed, Scopus, Web of science, Science Direct,
Ovid, ProQuest, IngentaConnect, and Wiley Online Library
(Supplementary Fig. 1). Toward that end, the medical subject
headings (MeSH) terms in PubMed and Scopus databases
using the search keywords “Toxoplasmosis”, “T. gondii”,  “Tox-
oplasma gondii”,  “Diabetes mellitus” and “Diabetic patients”
combined together using OR and/or AND. Also reference
lists of the primary relevance records found were explored 1 6;2  0(6):605–609
manually. Corresponding authors of papers were contacted
for more  details, if deemed necessary.
Study  selection  and  data  extraction
Only case–control studies on seroepidemiology of toxoplas-
mosis in diabetic individuals around the world were included.
Other inclusion criteria were as follows: diabetes as a disease
and T. gondii as an exposure, presence of healthy individ-
uals as control group, and serologic diagnostic test. Records
were evaluated by two independent reviewers. The selected
articles were scrutinized and contradictions among studies
were obviated by discussion and consensus. The data were
extracted carefully from databases on the basis of title, year
of publication, ﬁrst author, diagnostic method, type of inves-
tigation, type of disease, aim of study, main ﬁndings, exact
number of participants both in case and control groups, and
details of T. gondii positive individuals as well. The PRISMA
(preferred reporting items for systematic reviews and meta-
analysis) guideline17 was followed in the reporting of current
systematic review.
Meta-analysis
For each included study, the common odds ratio (OR) and
respective 95% conﬁdence interval (CI) on the association
among toxoplasmosis and diabetes were calculated. The out-
come of pool estimates of studies in addition to their 95% CI of
independent records were depicted in a forest plot. Cochran’s
Q and I2 statistics were applied to assess heterogeneity and
inconsistency, respectively. Furthermore, small study effects
and their publication bias were discerned by a funnel plot
on the cornerstone of Egger’s regression test. To comply with
the results of heterogeneity test, either Der Simonian and
Laird’s random-effects method or Mantel-Haenszel’s ﬁxed-
effects were employed to pool the approximations.
Results
Based on inclusion criteria, a total number of 7 out of 1377
studies were qualiﬁed to be ultimately included in this sys-
tematic review and meta-analysis,12,14,18–22 as demonstrated
in Supplementary Fig. 1. The speciﬁcations of each study com-
prising the number of cases and controls as well as the number
of IgG positive individuals, the utilized method and obtained
p-value have been summarized in Table 1. Out of 2248 per-
sons tested for toxoplasmosis infection, 717 were positive for
T. gondii infection, 202 had type 1, and 1158 had type 2 DM;  out
of 888 healthy individuals 280 positive for T. gondii infection.
The heterogeneity was statistically signiﬁcant, for both type
1, I2 = 94.7% and Q = 38.09 (p < 0.001), and type 2 DM,  I2 = 88.1%
and Q = 25.26 (p < 0.001) (Table 2 and Supplementary Fig. 2).
Accordingly, we calculated a common OR by random effects
model at 1.10 (95% CI = 0.13–9.57) with p = 0.929 and 2.39 (95%
CI = 1.20–4.75) with p = 0.013 for type 1 and type 2 DM,  respec-
tively (Table 2 and Supplementary Fig. 2). Also the calculated
common OR (random effects model) for both type 1 and 2 dia-
betes was 1.86 (95% CI = 0.93–3.74) with p = 0.0796. The test
of publication bias was clearly not signiﬁcant in this case,
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Table 1 – Prevalence of Toxoplasma infection among diabetic (cases) and healthy individuals (controls) included in the
systematic review.
Reference Diabetic patients
(cases)
Healthy individuals
(controls)
Matching Method OR (95% CI) p-Value
n Toxoplasma
IgG+ n (%)
n Toxoplasma
IgG+ n (%)
Type 1 diabetes
(14) 85 49 (57.6) 85 18 (21.1) Age and
gender
ELISA
(EUROIMMUN)
5.066 (2.579–9.952) <0.001
(21) 57 3 (5.2) 140 56 (40) Unspeciﬁed Bio-Plex 2200 kits 0.083 (0.025–0.279) <0.001
(20) 60 27 (45) 60 14 (23.3) Unspeciﬁed ELISA 2.688 (1.226–5.895) 0.01
Type 2 diabetes
(22) 807 457 (56.6) 250 56 (22.4) Age and
gender
ELISA
(EUROIMMUN)
4.523 (3.257–6.281) <0.001
(19) 91 55 (60.4) 93 36 (38.7) Age and
gender
ELISA (Pishtaz
Teb Zaman Co.)
2.419 (1.338–4.373) 0.003
(18) 150 79 (52.6) 150 76 (50.6) Gender ELISA (VIRO,
Germany).
1.083 (0.689–1.704) 0.72
(12) 110 47 (42.7) 110 24 (21.8) Age and
gender
ELISA (Biotech
Co. England)
2.673  (1.483–4.819) 0.001
n, number of individuals; IgG+, anti-Toxoplasma antibody (immunoglobulin G); (%), percentage; ELISA, enzyme-linked immunosorbent assay;
OR, odds ratio; 95% CI, 95 percent conﬁdence interval.
Table 2 – Subgroup analysis according to type of diabetes.
Type of diabetes No. of studies OR (95% CI) I2% Heterogeniety test
p Q
Type 1 3 1.10 (0.13–9.57) 94.7 38.09 <0.001
Type 2 4 2.39 (1.20–4.75) 88.1 25.26 <0.001
Overall 7 1.86 (0.93–3.74) 90.2 61.35 <0.001
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oTest for heterogeneity between subgroup Q: 0.703, p-value: 0.4.
 = 0.335 (Supplementary Fig. 3). Also, the chart of forest plot
as been illustrated in supplementary Fig. 2. The status of
oxoplasmosis infection was based on ELISA IgG, except for
ne paper in which the Bio-Plex 2200 kits were employed.
iscussion
 possible association between toxoplasmosis and DM would
ntail signiﬁcant clinical consequences, shedding light on
he complicated pathogenesis of DM.  Overall, the current
ypothesis suggests that toxoplasmosis increases suscepti-
ility to acquiring diabetes and, on the other hand, diabetic
atients are more  vulnerable to opportunistic infections such
s toxoplasmosis.12–14,22–24 Subsequently, to elucidate this
ssociation, various empirical evidence have been appraised
nd proposed as plausible pathophysiological mechanisms,
ncluding: (1) infected white blood cells represent enhanced
igratory feature, leading to the easier spread of Toxoplasma
n body organs, e.g. pancreas13; (2) a clinically conspicuous
utoimmune process could be ignited by T. gondii infection,
rending immune machinery toward autoantibody produc-
ion, for instance against -cells of Langerhans islets13; (3)
n light of ex vivo d-glucose and insulin dose-responsive
xperiment in 3T3-L1 cells, better replication of Toxoplasma
ccurs in insulin-producing -cells, leading to activation ofautoimmunity pathways as well as provoking the inﬂamma-
tion of Langerhans islets (insulitis) and ultimately developing
diabetes23; (4) a possibility, is that T. gondii itself may invade
and destroy pancreatic -cells directly, instigating pancreati-
tis and more  importantly, diabetes25; (5) production of reactive
oxygen species (ROS) and nitric oxide (NO) is induced by
diabetes, and these agents, as stimulant for intra-cellular
pathogens, can re-activate latent, cysts of parasites, again
initiating acute infection26; (6) given the inability of neu-
trophils to correctly perform phagocytosis and intra-cellular
killing in progressive phase of diabetes, there may be increased
responsiveness to intra-cellular pathogens such as Candida
and Toxoplasma,27 and (7) the opsonization activity and leuko-
cyte cytotoxicity of diabetic patients required for elimination
of pathogens are considerably subsided, hence they would be
more prone to opportunistic infections.12,27,28
In the included studies (Tables 1 and 2), the OR in type 1 DM
individuals was 1.10 (95% CI = 0.13–9.57) with p = 0.929, while
this ratio in type 2 DM patients was 2.39 (95% CI = 1.20–4.75)
with p = 0.013. Thus, the risk of type 1 and 2 diabetes with
previous Toxoplasma exposure would be 1.10 and 2.39 fold
higher, respectively, than for unexposed persons. However, no
statistically signiﬁcant association between chronic toxoplas-
mosis and type 1 DM was held on random effects model. In
this case, the highest OR (5.066) was reported in the study
by Gokce et al.14 (p < 0.001) and the lowest OR (0.083) in the
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study by Krause et al.21 (p < 0.001). According to the esti-
mated OR by Krause et al.21 there is no association between
toxoplasmosis and diabetes and it is hypothesized that the
patients’ younger ages as well as uncommon route of infec-
tion may have remarkably biased their results. Recently, some
researchers have demonstrated the inﬂuence of parasite geno-
types on behavior, psychomotor performance, physiology, and
overall health of their host. Hence, the strain of Toxoplasma
should be considered as an inﬂuential parameter in relation
to diabetes.15,16,29–32
Despite of the lack of remarkable correlation between
chronic toxoplasmosis and type 1 diabetes in the current
meta-analysis, ex vivo studies strongly demonstrate the pres-
ence of this relationship.13,24 Therefore, further studies are
needed in the future. There were several limitations in our
study, including (1) small sample sizes in included studies
and no further details about disease condition and duration
in cases; (2) the variable quality of reporting of studies; (3)
variable methodology to deﬁne Toxoplasma infection; and (4)
lack of representativeness of cases and controls as they were
selected from restricted communities, thus limiting external
validity of the results.
Implications  for  research
Based on currently available results, no statistically signiﬁ-
cant association was observed between chronic toxoplasmosis
and type 1 DM;  of course there remain many  questions to be
answered in future investigations.
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